Ozempic, Wegovy, other GLP-1RA drugs not linked to increased pancreatic cancer risk, study finds
Posted:
New research has concluded that drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer.
Antimicrobial resistance could claim almost two million lives a year by 2050. Now, researchers believe they could use #AI to predict which bugs will become resistant so that we can better prepare.
Read the full article here.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…